

Special Issue

Nucleic Acid Therapeutics (NATs): Advances and Perspectives

Message from the Guest Editors

The field of nucleic acid therapeutics (NATs) has attracted a tremendous amount of interest in the past few decades. The increasing number of approved nucleic acid drugs demonstrates the potential of these therapies to treat a variety of diseases from neuromuscular disorders to cancers. Nucleic acid therapeutics act via multiple mechanisms of action, including gene silencing, activation, modulation, replacement, or editing. Continuous advances in the chemistry and design of these cutting-edge genetic drugs have led to numerous successful clinical applications, eliciting even more interest from researchers, including both academic groups and drug development companies. The aim of this Special Issue is to cover recent advances in the field of nucleic acid therapeutics, including antisense oligonucleotides, small interfering RNA conjugates, lipid nanoparticles, and RNA and gene-editing technologies. We would like to put emphasis on their broad therapeutic potential due to the variety of mechanisms of action and the different tissues and diseases they can target. We invite contributions in the form of original research articles and reviews. We look forward to your contributions.

Guest Editors

Dr. Aurélie Goyenvalle

UVSQ, Inserm, END-ICAP, Université Paris-Saclay, Versailles, France

Dr. Simon Guiraud

UEVE, Inserm, Genethon, Université Paris-Saclay, Evry, France

Deadline for manuscript submissions

closed (20 March 2024)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/134886

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).